Artificial intelligence-assisted clinical decision support for childhood asthma management: A randomized clinical trial.

<h4>Rationale</h4>Clinical decision support (CDS) tools leveraging electronic health records (EHRs) have been an approach for addressing challenges in asthma care but remain under-studied through clinical trials.<h4>Objectives</h4>To assess the effectiveness and efficiency of...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Hee Yun Seol, Pragya Shrestha, Joy Fladager Muth, Chung-Il Wi, Sunghwan Sohn, Euijung Ryu, Miguel Park, Kathy Ihrke, Sungrim Moon, Katherine King, Philip Wheeler, Bijan Borah, James Moriarty, Jordan Rosedahl, Hongfang Liu, Deborah B McWilliams, Young J Juhn
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/ab490bfea96744adab6aec1d4f1843ae
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:ab490bfea96744adab6aec1d4f1843ae
record_format dspace
spelling oai:doaj.org-article:ab490bfea96744adab6aec1d4f1843ae2021-12-02T20:18:53ZArtificial intelligence-assisted clinical decision support for childhood asthma management: A randomized clinical trial.1932-620310.1371/journal.pone.0255261https://doaj.org/article/ab490bfea96744adab6aec1d4f1843ae2021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0255261https://doaj.org/toc/1932-6203<h4>Rationale</h4>Clinical decision support (CDS) tools leveraging electronic health records (EHRs) have been an approach for addressing challenges in asthma care but remain under-studied through clinical trials.<h4>Objectives</h4>To assess the effectiveness and efficiency of Asthma-Guidance and Prediction System (A-GPS), an Artificial Intelligence (AI)-assisted CDS tool, in optimizing asthma management through a randomized clinical trial (RCT).<h4>Methods</h4>This was a single-center pragmatic RCT with a stratified randomization design conducted for one year in the primary care pediatric practice of the Mayo Clinic, MN. Children (<18 years) diagnosed with asthma receiving care at the study site were enrolled along with their 42 primary care providers. Study subjects were stratified into three strata (based on asthma severity, asthma care status, and asthma diagnosis) and were blinded to the assigned groups.<h4>Measurements</h4>Intervention was a quarterly A-GPS report to clinicians including relevant clinical information for asthma management from EHRs and machine learning-based prediction for risk of asthma exacerbation (AE). Primary endpoint was the occurrence of AE within 1 year and secondary outcomes included time required for clinicians to review EHRs for asthma management.<h4>Main results</h4>Out of 555 participants invited to the study, 184 consented for the study and were randomized (90 in intervention and 94 in control group). Median age of 184 participants was 8.5 years. While the proportion of children with AE in both groups decreased from the baseline (P = 0.042), there was no difference in AE frequency between the two groups (12% for the intervention group vs. 15% for the control group, Odds Ratio: 0.82; 95%CI 0.374-1.96; P = 0.626) during the study period. For the secondary end points, A-GPS intervention, however, significantly reduced time for reviewing EHRs for asthma management of each participant (median: 3.5 min, IQR: 2-5), compared to usual care without A-GPS (median: 11.3 min, IQR: 6.3-15); p<0.001). Mean health care costs with 95%CI of children during the trial (compared to before the trial) in the intervention group were lower than those in the control group (-$1,036 [-$2177, $44] for the intervention group vs. +$80 [-$841, $1000] for the control group), though there was no significant difference (p = 0.12). Among those who experienced the first AE during the study period (n = 25), those in the intervention group had timelier follow up by the clinical care team compared to those in the control group but no significant difference was found (HR = 1.93; 95% CI: 0.82-1.45, P = 0.10). There was no difference in the proportion of duration when patients had well-controlled asthma during the study period between the intervention and the control groups.<h4>Conclusions</h4>While A-GPS-based intervention showed similar reduction in AE events to usual care, it might reduce clinicians' burden for EHRs review resulting in efficient asthma management. A larger RCT is needed for further studying the findings.<h4>Trial registration</h4>ClinicalTrials.gov Identifier: NCT02865967.Hee Yun SeolPragya ShresthaJoy Fladager MuthChung-Il WiSunghwan SohnEuijung RyuMiguel ParkKathy IhrkeSungrim MoonKatherine KingPhilip WheelerBijan BorahJames MoriartyJordan RosedahlHongfang LiuDeborah B McWilliamsYoung J JuhnPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 8, p e0255261 (2021)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Hee Yun Seol
Pragya Shrestha
Joy Fladager Muth
Chung-Il Wi
Sunghwan Sohn
Euijung Ryu
Miguel Park
Kathy Ihrke
Sungrim Moon
Katherine King
Philip Wheeler
Bijan Borah
James Moriarty
Jordan Rosedahl
Hongfang Liu
Deborah B McWilliams
Young J Juhn
Artificial intelligence-assisted clinical decision support for childhood asthma management: A randomized clinical trial.
description <h4>Rationale</h4>Clinical decision support (CDS) tools leveraging electronic health records (EHRs) have been an approach for addressing challenges in asthma care but remain under-studied through clinical trials.<h4>Objectives</h4>To assess the effectiveness and efficiency of Asthma-Guidance and Prediction System (A-GPS), an Artificial Intelligence (AI)-assisted CDS tool, in optimizing asthma management through a randomized clinical trial (RCT).<h4>Methods</h4>This was a single-center pragmatic RCT with a stratified randomization design conducted for one year in the primary care pediatric practice of the Mayo Clinic, MN. Children (<18 years) diagnosed with asthma receiving care at the study site were enrolled along with their 42 primary care providers. Study subjects were stratified into three strata (based on asthma severity, asthma care status, and asthma diagnosis) and were blinded to the assigned groups.<h4>Measurements</h4>Intervention was a quarterly A-GPS report to clinicians including relevant clinical information for asthma management from EHRs and machine learning-based prediction for risk of asthma exacerbation (AE). Primary endpoint was the occurrence of AE within 1 year and secondary outcomes included time required for clinicians to review EHRs for asthma management.<h4>Main results</h4>Out of 555 participants invited to the study, 184 consented for the study and were randomized (90 in intervention and 94 in control group). Median age of 184 participants was 8.5 years. While the proportion of children with AE in both groups decreased from the baseline (P = 0.042), there was no difference in AE frequency between the two groups (12% for the intervention group vs. 15% for the control group, Odds Ratio: 0.82; 95%CI 0.374-1.96; P = 0.626) during the study period. For the secondary end points, A-GPS intervention, however, significantly reduced time for reviewing EHRs for asthma management of each participant (median: 3.5 min, IQR: 2-5), compared to usual care without A-GPS (median: 11.3 min, IQR: 6.3-15); p<0.001). Mean health care costs with 95%CI of children during the trial (compared to before the trial) in the intervention group were lower than those in the control group (-$1,036 [-$2177, $44] for the intervention group vs. +$80 [-$841, $1000] for the control group), though there was no significant difference (p = 0.12). Among those who experienced the first AE during the study period (n = 25), those in the intervention group had timelier follow up by the clinical care team compared to those in the control group but no significant difference was found (HR = 1.93; 95% CI: 0.82-1.45, P = 0.10). There was no difference in the proportion of duration when patients had well-controlled asthma during the study period between the intervention and the control groups.<h4>Conclusions</h4>While A-GPS-based intervention showed similar reduction in AE events to usual care, it might reduce clinicians' burden for EHRs review resulting in efficient asthma management. A larger RCT is needed for further studying the findings.<h4>Trial registration</h4>ClinicalTrials.gov Identifier: NCT02865967.
format article
author Hee Yun Seol
Pragya Shrestha
Joy Fladager Muth
Chung-Il Wi
Sunghwan Sohn
Euijung Ryu
Miguel Park
Kathy Ihrke
Sungrim Moon
Katherine King
Philip Wheeler
Bijan Borah
James Moriarty
Jordan Rosedahl
Hongfang Liu
Deborah B McWilliams
Young J Juhn
author_facet Hee Yun Seol
Pragya Shrestha
Joy Fladager Muth
Chung-Il Wi
Sunghwan Sohn
Euijung Ryu
Miguel Park
Kathy Ihrke
Sungrim Moon
Katherine King
Philip Wheeler
Bijan Borah
James Moriarty
Jordan Rosedahl
Hongfang Liu
Deborah B McWilliams
Young J Juhn
author_sort Hee Yun Seol
title Artificial intelligence-assisted clinical decision support for childhood asthma management: A randomized clinical trial.
title_short Artificial intelligence-assisted clinical decision support for childhood asthma management: A randomized clinical trial.
title_full Artificial intelligence-assisted clinical decision support for childhood asthma management: A randomized clinical trial.
title_fullStr Artificial intelligence-assisted clinical decision support for childhood asthma management: A randomized clinical trial.
title_full_unstemmed Artificial intelligence-assisted clinical decision support for childhood asthma management: A randomized clinical trial.
title_sort artificial intelligence-assisted clinical decision support for childhood asthma management: a randomized clinical trial.
publisher Public Library of Science (PLoS)
publishDate 2021
url https://doaj.org/article/ab490bfea96744adab6aec1d4f1843ae
work_keys_str_mv AT heeyunseol artificialintelligenceassistedclinicaldecisionsupportforchildhoodasthmamanagementarandomizedclinicaltrial
AT pragyashrestha artificialintelligenceassistedclinicaldecisionsupportforchildhoodasthmamanagementarandomizedclinicaltrial
AT joyfladagermuth artificialintelligenceassistedclinicaldecisionsupportforchildhoodasthmamanagementarandomizedclinicaltrial
AT chungilwi artificialintelligenceassistedclinicaldecisionsupportforchildhoodasthmamanagementarandomizedclinicaltrial
AT sunghwansohn artificialintelligenceassistedclinicaldecisionsupportforchildhoodasthmamanagementarandomizedclinicaltrial
AT euijungryu artificialintelligenceassistedclinicaldecisionsupportforchildhoodasthmamanagementarandomizedclinicaltrial
AT miguelpark artificialintelligenceassistedclinicaldecisionsupportforchildhoodasthmamanagementarandomizedclinicaltrial
AT kathyihrke artificialintelligenceassistedclinicaldecisionsupportforchildhoodasthmamanagementarandomizedclinicaltrial
AT sungrimmoon artificialintelligenceassistedclinicaldecisionsupportforchildhoodasthmamanagementarandomizedclinicaltrial
AT katherineking artificialintelligenceassistedclinicaldecisionsupportforchildhoodasthmamanagementarandomizedclinicaltrial
AT philipwheeler artificialintelligenceassistedclinicaldecisionsupportforchildhoodasthmamanagementarandomizedclinicaltrial
AT bijanborah artificialintelligenceassistedclinicaldecisionsupportforchildhoodasthmamanagementarandomizedclinicaltrial
AT jamesmoriarty artificialintelligenceassistedclinicaldecisionsupportforchildhoodasthmamanagementarandomizedclinicaltrial
AT jordanrosedahl artificialintelligenceassistedclinicaldecisionsupportforchildhoodasthmamanagementarandomizedclinicaltrial
AT hongfangliu artificialintelligenceassistedclinicaldecisionsupportforchildhoodasthmamanagementarandomizedclinicaltrial
AT deborahbmcwilliams artificialintelligenceassistedclinicaldecisionsupportforchildhoodasthmamanagementarandomizedclinicaltrial
AT youngjjuhn artificialintelligenceassistedclinicaldecisionsupportforchildhoodasthmamanagementarandomizedclinicaltrial
_version_ 1718374244973281280